EGFR (21%), PTEN (17%), and NF1 (12%) mutations in the high-glioma risk score group and CIC (28%), FUBP1 (11%), and NOTCH1 (10%) mutations in the low-risk score group were identified (Figures 3D, E), and the mutation frequency of these genes was greater than 10%. This evidence concerns the gene EGFR and central nervous system cancer.